197.78 0.00 (0.00%)
After hours: 4:27PM EDT
|Bid||197.78 x 100|
|Ask||198.20 x 200|
|Day's range||197.30 - 203.95|
|52-week range||184.50 - 256.80|
|PE ratio (TTM)||6.03|
|Earnings date||1 Nov 2017|
|Dividend & yield||2.80 (1.36%)|
|1y target est||265.94|
Not even Botox can wipe away the worry lines that followed Allergan’s (AGN) recent patent loss. Yesterday, a federal district court judge invalidated some of the patents protecting blockbuster dry-eye treatment Restasis, opening the door for generic rivals that could shove sales of Allergan’s second-biggest selling drug righ off a cliff. Many argue that the event is already baked into Allergan’s stock price, as is the public relations backlash from the controversial deal the drug maker struck last month with the Saint Regis Mohawk Tribe of upstate New York to block its Restasis patents from scrutiny by the U.S. Patent and Trade Office.
Allergan already faced a "public relations backlash" after transferring the rights to its Restasis patents to a Native American tribe.
A U.S. District Court ruled patents for one of Allergan’s best-selling drugs are invalid, potentially opening the door for generic competition.
With its stock price in a free fall after a federal judge invalidated patents covering the dry eye drug Restasis, what’s next for Allergan (AGN). ... a generic version of Restasis has not yet been approved and even if a generic were approved within that time frame, a launch prior to the conclusion of that appeal would be considered ''at-risk''. Today’s court ruling is the latest development in the legal dispute pitting Allergan against a group of generic drug makers led by Teva Pharmaceutical Industries (TEVA) and Mylan (MYL).
Allergan had made a widely-criticized agreement with an American Indian tribe to defend a key product. This lawsuit could render it all moot.
Allergan PLC shares dropped 5% in extremely heavy afternoon trade Monday after a Texas district court judge ruled against the company in a patent lawsuit regarding the company's key billion-dollar dry ...
Generic-drug company Mylan has fired back at rival Allergan’s attempt to shield its top-selling eye medication from competition by transferring the patents to an Indian tribe.
Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.
Looking for some investments in the healthcare sector that aren't priced at a high premium? Allergan, Gilead Sciences, and DaVita are an excellent place to start.
Bigwigs of late have been investing a substantial portion of their R&D sources for the treatment of Non-Alcoholic Steatohepatitis (NASH).
Ardelyx's (ARDX) tenapanor reduces abdominal pain and improves bowel movements in a phase III study evaluating the drug in irritable bowel syndrome with constipation.
Allergan plc (AGN) announced that the FDA has accepted the new drug application (NDA) for ulipristal acetate, for the treatment of abnormal uterine bleeding in women with uterine fibroids.
The group is the latest to call on lawmakers to examine Allergan's controversial patent deal with a Native American tribe.
In September, Allergan struck an unusual deal with the Saint Regis Mohawk Tribe to transfer...
Shares of Valeant Pharmaceuticals International (VRX) are falling today despite a bullish analyst note that suggests the troubled drug maker’s biggest-selling drugs could grow market share in the next year. Deutsche Bank’s Gregg Gilbert and Greg Fraser conducted a survey of 25 primary care physicians who frequently prescribe treatments for irritable bowel syndrome inorder to assess their views on Valeant’s Xifaxan and two rival drugs from Allergan (AGN). The pair expect accelerating sales growth for Xifaxan, but flat sales for Allergan’s Viberzi and slowing growth for Linzess.
Generic competition is good, but the law Congress passed in 2011 puts unfair burdens on innovators.
Allergan struck a deal with an American Indian tribe to help protect its Restasis from competition—but the agreement has attracted criticism and lawmaker scrutiny.
“They would only do that if they felt a kind of arrogant confidence that they can continue to get away with murder,” Welch told MarketWatch.
Allergan's unusual deal to shield Restasis from certain patent challenges has drawn scrutiny from competitors, lawmakers and now a federal judge.
The FDA approval of Mylan's (MYL) generic version of Teva's Copaxone was the main news this week. Allergan was also in the headlines related to its deal with the Saint Regis Mohawk Tribe.